Chronic kidney disease
(CKD) and mineral disorders are one of the most common reasons of cats.
Alterations in mineral metabolism occur in early stage of CKD and increasing
the severity in advanced stages. In Turkey, although some clinical studies on
CKD in cats are available, no data concerning the clinical significance of
pretreatment Ca-P solubility product is present. The purpose of the current
study was to determine of Ca-P solubility product and its association with the
life quality of cats with CKD. Staging system for classifying cats with chronic
kidney disease was based on IRIS guideline. The following groups were occurred
based on serum creatinine (SCr) and urine specific gravity < 1035: Stage 2=
SCr 1.6 - 2.8 mg/dl; Stage 3= SCr 2.9 - 5.0 mg/dl; Stage 4= SCr > 5.0 mg/dl.
Solubility product (calcium x phosphorus) was also defined. Although calcium
levels were within reference ranges in groups, Ca-P product were above 72 mg2/dl2
in stage 3 and 4 cats. In conclusion, determination of pretreatment Ca-P solubility
product in cats with different stages of CKD could be useful to modify and
manage the life quality of cats with CKD.
Birincil Dil | İngilizce |
---|---|
Konular | Veteriner Cerrahi |
Bölüm | Makaleler |
Yazarlar | |
Yayımlanma Tarihi | 9 Eylül 2019 |
Yayımlandığı Sayı | Yıl 2019Cilt: 66 Sayı: 4 |